immutep
collaborate
labcorp
develop
oncology
services
products
sydney
australia
globe
newswire
immutep
limited
asx
imm
nasdaq
immp
biotechnology
company
developing
novel
immunotherapy
treatments
cancer
autoimmune
disease
pleased
announce
entered
licence
collaboration
agreement
labcorp
support
development
products
services
years
immutep
generated
significant
amount
specifically
terms
said
marc
voigt
ceo
immutep
terms
agreement
immutep
eligible
receive
potential
undisclosed
milestone
payments
collaboration
labcorp
unrelated
immutep
pharmaceutical
development
programs
cancer
autoimmune
disease
immutep
immutep
globally
active
biotechnology
company
leader
development
related
immunotherapeutic
products
treatment
cancer
autoimmune
disease
immutep
dedicated
leveraging
technology
expertise
bring
innovative
treatment
options
market
patients
maximize
value
shareholders
immutep
listed
australian
securities
exchange
imm
nasdaq
immp
united
states
immutep
current
lead
product
candidate
eftilagimod
alpha
efti
soluble
protein
based
immune
control
mechanism
mechanism
plays
vital
role
regulation
cell
immune
response
efti
currently
evaluated
combination
chemotherapy
treatment
metastatic
breast
cancer
phase
iib
clinical
trial
termed
aipac
identifier
phase
ii
clinical
trial
conducted
collaboration
merck
kenilworth
nj
usa
known
msd
outside
united
states
canada
referred
evaluate
combination
efti
pembrolizumab
several
different
solid
tumours
identifier
phase
clinical
trial
conducted
collaboration
merck
kgaa
darmstadt
germany
pfizer
referred
evaluate
combination
efti
avelumab
identifier
phase
combination
therapy
trial
metastatic
melanoma
termed
identifier
additional
products
including
antibodies
immune
response
modulation
autoimmunity
cancer
developed
immutep
large
pharmaceutical
partners
immutep
also
developing
agonist
autoimmune
disease
information
found
company
website
contacting
media
tim
mccarthy
lifesci
advisors
tim
